Charles Schwab Investment Management Inc. increased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – ...
PNC Financial Services Group Inc. boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 1.2% in ...
BridgeBio Pharma Inc. jumped the most in 16 months after its drug got US regulators’ nod to treat a rare, deadly form of ...
The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...
Wolfe has downgraded Alnylam Pharmaceuticals (NASDAQ:ALNY) to underperform from peer perform as it issues a contrarian view ...
But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...
Alnylam Pharmaceuticals has revealed new interim data from its Phase I trial of nucresiran, a ribonucleic acid interference ...
Financial giants have made a conspicuous bearish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam Pharmaceuticals (NASDAQ:ALNY) revealed 11 unusual trades. Delving into ...
Fintel on MSN12d
Wolfe Research Downgrades Alnylam Pharmaceuticals (ALNY)Fintel reports that on November 12, 2024, Wolfe Research downgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) ...
The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), with a ...
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) has shared new findings from its Phase 1 study of nucresiran (previously known as ALN-TTRsc04), a next-generation RNAi therapy being developed for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback